Semaglutide

Overview

Semaglutide is the active ingredient. Ozempic and Rybelsus are FDA-approved for type 2 diabetes; Wegovy is approved for chronic weight management and cardiovascular risk reduction in certain adults.

How It Works

It activates GLP-1 receptors, increasing glucose-dependent insulin release, slowing stomach emptying and reducing appetite.

Approved Uses

Indications differ by product. Always check the specific product label — the same ingredient may be approved for different uses.

Clinical Evidence

The STEP and SELECT trial programs studied weight and cardiovascular outcomes; SUSTAIN studied type 2 diabetes.

Common Side Effects

Nausea, diarrhea, vomiting, constipation and abdominal pain.

Important Warnings

Boxed warning regarding thyroid C-cell tumors; not for people with a personal or family history of medullary thyroid carcinoma or MEN 2.

Questions to Ask Your Healthcare Provider

• Is a GLP-1 medication appropriate for my health history?
• Which product and indication applies to me?
• What side effects should I watch for?
• How should I adjust nutrition and exercise?
• What happens if I stop the medication?

References

FDA product labeling and published trial reports. Full citations will be listed here.